Astrana Health (ASTH) Current Deferred Revenue (2023 - 2025)

Astrana Health has reported Current Deferred Revenue for 3 years, with the latest figure at $2.7 million in Q4 2025.

• Quarterly Current Deferred Revenue rose 65.57% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (up 65.57% YoY) and the FY2025 annual result came in at $2.7 million, up 65.57% from the prior year.
• Current Deferred Revenue grew to $2.7 million in Q4 2025 per ASTH's latest filing, from $686000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $2.7 million in Q4 2025 and troughed at $686000.0 in Q1 2025.
• A 3-year average of $1.7 million and a median of $1.9 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue jumped 115.86% in 2024, then soared 65.57% in 2025.
• Over 3 years, Current Deferred Revenue stood at $744000.0 in 2023, then surged by 115.86% to $1.6 million in 2024, then jumped by 65.57% to $2.7 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $2.7 million, $686000.0, and $1.6 million for Q4 2025, Q1 2025, and Q4 2024 respectively.